Its efficacy is significantly tied to specific mutation types; patients with exon 13 mutations in KIT, wild-type GIST, or exon 18 D842V mutation in PDGFRA show inherent resistance to imatinib 8. This evidence concerns the gene KIT and gastrointestinal stromal tumor.